Endocyte, a biotech company involved in chemotherapeutics aimed at cancer cells, has been awarded $3.5 million in federal and state grants to finish research expected to lead to clinical trials. The West Lafayette, Ind., company hopes to be able to stimulate cancer cells to take in vitamin foliate molecules treated with anti-cancer drugs, allowing the treatment to avoid harming normal cells.

Related Summaries